Releases
RXRX
9.97
-1.97%
-0.20
  • All
  • Financials
  • Insiders
More
Webull provides the latest Recursion Pharmaceuticals, Inc. (RXRX) stock and general news. This information may help you make smarter investment decisions.
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. The Company’s platform, Recursion Operating System (OS), is built with diverse technologies and enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. It integrates physical and digital components as iterative loops of atoms and bits of wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is an orally bioavailable, superoxide, scavenger small molecule being developed for the treatment of cerebral cavernous malformation (CCM). REC-2282 is developed for the treatment of neurofibromatosis type 2.